J Urol: 前列腺癌发生率和前列腺特异抗原筛选流行度分析

2017-10-13 AlexYang MedSci原创

在美国国家预防服务工作组(USPSTF)推荐的预防常规PSA工作之后,前列腺特异性抗原(PSA)筛选和前列腺癌发生率的减少是否与社会经济组织和美国人口普查区域之间是相似的这个问题仍旧不清楚。最近,有研究人员通过调查年龄、种族、疾病阶段、美国地区和区域社会经济状态分析了前列腺癌发生率和PSA筛选流行度。研究人员调查了年度百分比变化速率,并计算了边际概率和95%置信区间(CI)来评估PSA筛选流行度变

在美国国家预防服务工作组(USPSTF)推荐的预防常规PSA工作之后,前列腺特异性抗原(PSA)筛选和前列腺癌发生率的减少是否与社会经济组织和美国人口普查区域之间是相似的这个问题仍旧不清楚。最近,有研究人员通过调查年龄、种族、疾病阶段、美国地区和区域社会经济状态分析了前列腺癌发生率和PSA筛选流行度。研究人员调查了年度百分比变化速率,并计算了边际概率和95%置信区间(CI)来评估PSA筛选流行度变化。

研究发现,不小于50岁男性的发生率在所有种族、地区和SES组中减少。从2007年到2013年,局部癌症的总发生率在50岁-74岁中每年显著地减少7.5%(95% CI; -10.5, -4.4),在不小于75岁男性中卫11.1%(95% CI; -14.1, -8.1)。与之相反,2008年-2013年期间,晚期癌症的发生率在50-74岁男性中每年显著的增加1.4%(95% CI; 0.3, 2.5),但是在2011年到2013年期间的年龄不小于75岁男性中保持稳定(每年5.1%,95% CI; -3.4, 14.4)。在50-74岁男性中,晚期癌症随着贫穷程度的增加而增加,但是在不小于75岁男性中没有这种趋势。

最后,研究人员指出,在USPSTF推荐的针对常规PSA筛选之后,前列腺癌发生率在早期疾病的50岁以及更大的男性中减少,然而,晚期疾病在50-74岁男性中轻微增加。进一步的研究是需要的,从而证实他们的研究并且控制晚期疾病对前列腺癌致死率的影响。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1826383, encodeId=a065182638327, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Feb 10 16:56:00 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651422, encodeId=2680165142284, content=<a href='/topic/show?id=3e8a653e2fe' target=_blank style='color:#2F92EE;'>#流行度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65372, encryptionId=3e8a653e2fe, topicName=流行度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acc724200297, createdName=piaojinhua, createdTime=Thu Jun 28 21:56:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584384, encodeId=b5d7158438460, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Sun Oct 15 11:56:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623256, encodeId=3a40162325657, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Sun Oct 15 11:56:00 CST 2017, time=2017-10-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1826383, encodeId=a065182638327, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Feb 10 16:56:00 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651422, encodeId=2680165142284, content=<a href='/topic/show?id=3e8a653e2fe' target=_blank style='color:#2F92EE;'>#流行度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65372, encryptionId=3e8a653e2fe, topicName=流行度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acc724200297, createdName=piaojinhua, createdTime=Thu Jun 28 21:56:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584384, encodeId=b5d7158438460, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Sun Oct 15 11:56:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623256, encodeId=3a40162325657, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Sun Oct 15 11:56:00 CST 2017, time=2017-10-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1826383, encodeId=a065182638327, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Feb 10 16:56:00 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651422, encodeId=2680165142284, content=<a href='/topic/show?id=3e8a653e2fe' target=_blank style='color:#2F92EE;'>#流行度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65372, encryptionId=3e8a653e2fe, topicName=流行度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acc724200297, createdName=piaojinhua, createdTime=Thu Jun 28 21:56:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584384, encodeId=b5d7158438460, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Sun Oct 15 11:56:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623256, encodeId=3a40162325657, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Sun Oct 15 11:56:00 CST 2017, time=2017-10-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1826383, encodeId=a065182638327, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat Feb 10 16:56:00 CST 2018, time=2018-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651422, encodeId=2680165142284, content=<a href='/topic/show?id=3e8a653e2fe' target=_blank style='color:#2F92EE;'>#流行度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65372, encryptionId=3e8a653e2fe, topicName=流行度)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acc724200297, createdName=piaojinhua, createdTime=Thu Jun 28 21:56:00 CST 2018, time=2018-06-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1584384, encodeId=b5d7158438460, content=<a href='/topic/show?id=9bbee5948f0' target=_blank style='color:#2F92EE;'>#筛选#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75948, encryptionId=9bbee5948f0, topicName=筛选)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39da17047364, createdName=ms6747015003810650, createdTime=Sun Oct 15 11:56:00 CST 2017, time=2017-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1623256, encodeId=3a40162325657, content=<a href='/topic/show?id=62a655263e9' target=_blank style='color:#2F92EE;'>#抗原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55263, encryptionId=62a655263e9, topicName=抗原)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f59b20519025, createdName=xiaoyeshuang, createdTime=Sun Oct 15 11:56:00 CST 2017, time=2017-10-15, status=1, ipAttribution=)]

相关资讯

J Patient Exp:前列腺癌病人中护士主导的电话服务模式

医疗健康成本的不断增加促使了人们对更加有效的利用和分配医疗资源进行重新的思考。护士主导的PSA电话跟踪服务也许为降低医疗健康成本提供了一个合适的选择。最近,有研究人员招募了815名病人,并参与了护士主导的稳定的前列腺癌电话跟踪服务。研究人员选择了一个方便的样本用来进行邮递形式的问卷调查评估,主要评估内容是病人的满意度。研究中的815名病人在为期10年的跟踪服务中电话次数高达3683次。大多数病人对

Brit J Cancer:IGF-1R与前列腺癌根治性放射治疗后的不良结果有关

激活类型1类胰岛素生长因子受体(IGF-1Rs)经历内化和核转移可以促进细胞生存。之前,研究人员报道了IGF-1R抑制剂推迟了损伤修复,并且可以使前列腺癌细胞对电离辐射敏感。最近,他们又探究了这些发现的临床相关性。研究人员通过免疫组化技术评估了IGF-1R和临床治疗结果的相关性,样本为136名男性的诊断性活检样本,并且这些男性因前列腺癌接受了55-70Gy体外放射治疗;研究人员还在外科治疗病人中的

J Cancer:警惕!牙周病可增加前列腺癌的发病率!

由于人口老龄化,预计前列腺癌(PC)伴牙周病(PD)的发病率都会增加。本研究旨在通过使用国家健康保险服务-健康检查组(NHIS-HEC)中的数据来确定PD与PC之间的关联。2002年至2013年,通过随机分层抽样从NHIS数据库收集了187934名韩国人。在调整潜在的混杂因素(性别,年龄,家庭收入,保险状况,居住面积,高血压,糖尿病,脑梗塞,心绞痛,心肌梗塞,吸烟状况,酒精摄入和规律运动)的同时,

治疗特定前列腺癌,**新药有望近期上市

杨森(Janssen)公司今天宣布,该公司已经向FDA提交了一份新药申请,使用apalutamide(ARN-509),一款下一代口服雄激素受体抑制剂(AR),治疗非转移性去势抵抗性前列腺癌。目前,尚没有FDA批准的疗法针对此类疾病。

Oncogene:调控回路HP1γ/miR-451a/c-Myc可以促进前列腺癌恶化

有研究已经表明异染色质蛋白1γ(HP1γ)在各种癌症类型中具有致癌作用。然而,HP1γ在前列腺癌(PCa)恶化中的角色和潜在的分子机制仍旧有很多未知。最近,有研究人员发现HP1γ在前列腺癌中表达上调,并且HP1γ在前列腺癌中的水平有所提高,这也可以预测不良的治疗结果。另外,HP1γ蛋白在前列腺癌细胞中的缺失不仅抑制的癌细胞的增殖和诱导细胞凋亡,还可以一定程度的组织致瘤性。研究人员还发现了c-Myc

Cancer Lett:卡巴他赛聚合物纳米粒子可以用来治疗多烯紫杉醇抗性和骨转运前列腺癌

转移性去势难治性前列腺癌(mCRPC)有效的治疗到目前为止仍旧是一个挑战。卡巴他赛(CBZ)是被批准用于多烯紫杉醇治疗失败的药物,但是生存期的改善仅仅只有大约2个月,并且病人要承受显著的负作用。最近,有研究人员报道了一个关于卡巴他赛的基于聚合物传递系统的开发和研究,目的是提高卡巴他赛的安全性和对DTX抗性mCRPC治疗的有效性。CBZ结合到一种羧甲基纤维素聚合物上(Cellax-CBZ),并且可以